Interleukin 10 (IL-10)
Interleukin-10 (IL-10) is a critical anti-inflammatory cytokine with potent immunoregulatory functions. Produced primarily by immune cells including monocytes, macrophages, dendritic cells, regulatory T-cells, and B-cells, IL-10 modulates immune responses by suppressing excessive inflammation and preventing chronic autoimmune reactions. Its primary mechanism involves binding to the IL-10 receptor, activating the signal transducer and activator of transcription 3 (STAT3) pathway. This activation induces anti-inflammatory gene expression while inhibiting pro-inflammatory cytokines, effectively balancing the immune response and promoting tissue homeostasis.
IL-10 deficiency or low production is associated with excessive and chronic immune activation, often leading to autoimmune and inflammatory diseases. Low levels of IL-10 have been linked with inflammatory bowel disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, type 1 diabetes mellitus, and enhanced rejection risk in organ transplantation due to immune dysregulation.
Conversely, elevated IL-10 levels can occur in chronic infectious conditions (e.g., HIV, tuberculosis, hepatitis B and C infections), malignancies, and sepsis, reflecting the body's attempt to mitigate ongoing systemic inflammation and immune activation. Persistently high IL-10 levels in such conditions may contribute to immune suppression, potentially worsening disease outcomes.
- As an aid for the diagnosis and monitoring of inflammatory and autoimmune conditions
- Assessment of disease severity and immune status in chronic infections and malignancies
- Evaluation of immune status in sepsis or systemic inflammatory response syndrome (SIRS)
- Monitoring immune responses and rejection risk in transplant patients
Increased IL-10 levels:
- Chronic infections (HIV, tuberculosis, hepatitis B & C)
- Malignancies (cancers associated with immune suppression)
- Sepsis or systemic inflammatory response syndrome (SIRS)
Decreased IL-10 levels:
- Inflammatory bowel diseases (Crohn’s disease, ulcerative colitis)
- Autoimmune disorders (rheumatoid arthritis, psoriasis, multiple sclerosis, type 1 diabetes mellitus)
- Increased risk of transplant rejection due to reduced immune regulation
<2.8 pg/mL
Serum (SST tube).
Stability
- Ambient: 1 hour
- Refrigerated: unacceptable
- Frozen: 1 year
- Immunol Rev. 2008;226:205–218. ]PMID: 19161426]
- Annu Rev Immunol. 2011;29:71–109. [PMID: 21166540]
- N Engl J Med. 2009;361(21):2033–2045. [PMID: 19890111]
- Cell Biochem Biophys. 2014 Sep;70(1):37-49. [PMID: 24639111]
- J Exp Med. 2020 Jan 6;217(1):e20190418. [PMID: 31611251]
- Cytokine Growth Factor Rev. 2010 Oct;21(5):331-44. [PMID: 21115385]
- Annu Rev Immunol. 2001;19:683-765. [PMID: 11244051]
- Front Immunol. 2023 Jun 8;14:1161067. [PMID: 37359549]